Veraxa Biotech AG - Post De-SPAC current report, Q4 FY2026

Veraxa Biotech AG — Form 6-K Summary

Reporting context: Foreign private issuer; Form 6-K filed November 19, 2026, covering the month of November 2026. The filing reports a shareholder meeting notice, not financial results.

Business and meeting context

On November 18, 2026, Veraxa Biotech AG issued notice of an Extraordinary General Meeting scheduled for December 10, 2026. November 13, 2026 was set as the record date for determining shareholders entitled to receive notice. The notice is identified as Exhibit 99.1, but its text is not included in the provided filing content.

Financial performance and changes

The filing provides no revenue, profit, cash flow, margin, debt, liquidity, guidance, or prior-period comparison data.

Outlook, risks, and unusual items

No financial outlook, management commentary, risks, contingencies, or unusual financial items are described in the provided text. The reported item is the calling of an extraordinary shareholder meeting.

Key facts to verify

  • Review Exhibit 99.1 for the meeting agenda, proposed resolutions, and any associated deadlines or implications.
  • Confirm the meeting outcome and any subsequent company disclosures.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.